AxoGen, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDAxoGen, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 91), indicating clear outperformance against the broad market. Earnings contraction of 348% provides fundamental context to the price action. Investors should exercise caution due to high volatility (54% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $42.63 | +5.39% | ABOVE |
| 50 SMA | $41.51 | +8.24% | ABOVE |
| 100 SMA | $37.06 | +21.24% | ABOVE |
| 150 SMA | $35.14 | +27.87% | ABOVE |
| 200 SMA | $31.11 | +44.44% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is AXGN in an uptrend right now?
AXGN has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, AXGN is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is AXGN overbought or oversold?
AXGN's RSI (14) is 58. The stock is in neutral territory, neither overbought nor oversold.
Is AXGN outperforming the market?
AXGN has a Relative Strength (RS) Rating of 91 out of 99. Yes, AXGN is a market leader, outperforming 91% of all stocks over the past 12 months.
Where is AXGN in its 52-week range?
AXGN is trading at $44.93, which is 98% of its 52-week high ($46.00) and 97% above its 52-week low ($10.50).
How volatile is AXGN?
AXGN has a Beta of 0.84 and 52-week volatility of 54%. It's less volatile than the S&P 500 - generally more stable.